Sanjiv Sharma, MD
Internal Medicine · Toms River, NJNPI 1285607739
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,565 of the $6,838 with a category attached, or 66.8%. 16 manufacturers reported payments, led by Eisai Inc. at 44.2% of the total. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $94.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$3K
- Sage Therapeutics, LLC$2K
- Lilly USA, LLC$1K
- Biogen$269
- Medtronic$205
- Novartis$171
- plus $366 from 10 others
Across 1,471 payments — averaging $23,044 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$11M
- Eli Lilly$9.5M
- Eisai Inc.$9.1M
- Genentech, Inc.$2.8M
- AbbVie$648K
- Sage Therapeutics, LLC$209K
- plus $595K from 7 others
What the payments were for
- Travel & lodging$4,56567%
- Food & beverage$2,27333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 29 | $3,022 |
| Sage Therapeutics, LLC | 12 | $1,522 |
| Lilly USA, LLC | 4 | $1,284 |
| Biogen | 3 | $269 |
| Medtronic(2 entities) | 2 | $205 |
| Novartis | 8 | $171 |
| AbbVie | 1 | $124 |
| Eli Lilly | 1 | $60 |
| Astellas Pharma US Inc | 3 | $41 |
| Pfizer | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Nevro Corp. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,838 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $45,638 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $28,341 |
| EliquisApixaban | 22 | $22,040 |
| JanuviaSitagliptin Phosphate | 27 | $20,390 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $16,427 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,815 |
| MyrbetriqMirabegron | 12 | $9,240 |
| TradjentaLinagliptin | 11 | $5,320 |
| Rosuvastatin Calcium | 230 | $3,970 |
| Lubiprostone | 13 | $2,147 |
| Glipizide-MetforminGlipizide/Metformin Hcl | 25 | $2,091 |
| Levothyroxine Sodium | 149 | $2,025 |
| Nebivolol Hcl | 29 | $1,877 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 103 | $1,831 |
| Atorvastatin Calcium | 150 | $1,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $14 | $48,73163 claims |
| Novo NordiskOzempic | $14 | $45,63827 claims |
| PfizerEliquis | $29 | $22,04022 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $9,24012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Toms River
- Samir JainToms River$32K
- Akshay PatelToms River$27K
- Ralph GuarinoToms River$26K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.